Sexually Transmitted Diseases, Viral
11
1
2
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.1%
1 terminated out of 11 trials
87.5%
+1.0% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
WiseApp for Spanish Speakers Living With HIV
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
HIV Indicator Diseases in Hospital and Primary Care
Psychoeduc Interv. Through Meta-universes on Condom's Use Self - Efficacy and Sexual Behavior in Students of UAChile
Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
Group Therapies for Reducing HIV-risk Behavior in Women Who Have Survived Childhood Sexual Abuse
Measuring Responses to Sublingual Antigens